Top Markets
Coin of the day
Merck & Co., Inc. Merck & Co., Inc.

Merck & Co., Inc.

MRK
Rang in Aktien #40
Merck & Co., Inc. is a global healthcare leader with operations spanning two... Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
Aktienkurs
$152.37
Marktkapitalisierung
$376.33B
Veränderung (1 Tag)
12.46%
Veränderung (1 Jahr)
79.41%
Land
US
Handel Merck & Co., Inc. (MRK)

Kategorie

Gewinn für Merck & Co., Inc. (MRK)
Gewinn im Jun 2026 TTM: $5.95B
Laut den aktuellen Finanzberichten von Merck & Co., Inc. betragen die aktuellen Gewinne des Unternehmens $5.95B. Im Jahr 2024 erzielte das Unternehmen einen Gewinn von $19.94B, eine Steigerung gegenüber dem Gewinn im Jahr 2023, der $1.89B betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Merck & Co., Inc. von 2000 bis 2026
Gewinn am Ende jedes Jahres
Jahr Gewinn ändert
2026 (TTM) $5.95B -71.77%
2025 $21.07B 5.67%
2024 $19.94B 955.37%
2023 $1.89B -88.51%
2022 $16.44B 18.48%
2021 $13.88B 136.72%
2020 $5.86B -18.24%
2019 $7.17B -17.58%
2018 $8.70B 33.43%
2017 $6.52B 39.97%
2016 $4.66B -13.74%
2015 $5.40B -68.75%
2014 $17.28B 211.69%
2013 $5.55B -36.55%
2012 $8.74B 19.16%
2011 $7.33B 343.68%
2010 $1.65B -89.19%
2009 $15.29B 53.96%
2008 $9.93B 194.63%
2007 $3.37B -45.82%
2006 $6.22B -15.51%
2005 $7.36B -7.98%
2004 $8.00B -11.59%
2003 $9.05B -6.22%
2002 $9.65B -2.98%
2001 $9.95B 1.26%
2000 $9.82B 0.00%
Gewinn ähnlicher Unternehmen oder Konkurrenten
Unternehmen Gewinn Gewinnunterschied Land
$33.59B 464.80%
US
$25.20B 323.60%
US
$8.70B 46.25%
US
$21.39B 259.59%
CH
$16.38B 175.36%
CH